Does the media favor ARWR or BIIB?

In the previous week, Biogen had 11 more articles in the media than Arrowhead Pharmaceuticals. MarketBeat recorded 19 mentions for Biogen and 8 mentions for Arrowhead Pharmaceuticals. Biogen's average media sentiment score of 0.74 beat Arrowhead Pharmaceuticals' score of 0.26 indicating that Biogen is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Arrowhead Pharmaceuticals 0 Very Positive mention(s) 3 Positive mention(s) 3 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Neutral Biogen 7 Very Positive mention(s) 4 Positive mention(s) 5 Neutral mention(s) 1 Negative mention(s) 1 Very Negative mention(s) Positive

Does the media refer more to ALNY or ARWR?

In the previous week, Alnylam Pharmaceuticals had 8 more articles in the media than Arrowhead Pharmaceuticals. MarketBeat recorded 16 mentions for Alnylam Pharmaceuticals and 8 mentions for Arrowhead Pharmaceuticals. Alnylam Pharmaceuticals' average media sentiment score of 0.51 beat Arrowhead Pharmaceuticals' score of 0.26 indicating that Alnylam Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Alnylam Pharmaceuticals 4 Very Positive mention(s) 2 Positive mention(s) 5 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Positive Arrowhead Pharmaceuticals 0 Very Positive mention(s) 3 Positive mention(s) 3 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media prefer ARWR or ROIV?

In the previous week, Roivant Sciences had 4 more articles in the media than Arrowhead Pharmaceuticals. MarketBeat recorded 12 mentions for Roivant Sciences and 8 mentions for Arrowhead Pharmaceuticals. Roivant Sciences' average media sentiment score of 0.64 beat Arrowhead Pharmaceuticals' score of 0.26 indicating that Roivant Sciences is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Arrowhead Pharmaceuticals 0 Very Positive mention(s) 3 Positive mention(s) 3 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Neutral Roivant Sciences 6 Very Positive mention(s) 2 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media refer more to BNTX or ARWR?

In the previous week, BioNTech had 14 more articles in the media than Arrowhead Pharmaceuticals. MarketBeat recorded 22 mentions for BioNTech and 8 mentions for Arrowhead Pharmaceuticals. BioNTech's average media sentiment score of 0.46 beat Arrowhead Pharmaceuticals' score of 0.26 indicating that BioNTech is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment BioNTech 9 Very Positive mention(s) 3 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Arrowhead Pharmaceuticals 0 Very Positive mention(s) 3 Positive mention(s) 3 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media refer more to INSM or ARWR?

In the previous week, Insmed had 4 more articles in the media than Arrowhead Pharmaceuticals. MarketBeat recorded 12 mentions for Insmed and 8 mentions for Arrowhead Pharmaceuticals. Arrowhead Pharmaceuticals' average media sentiment score of 0.26 beat Insmed's score of 0.05 indicating that Arrowhead Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Insmed 1 Very Positive mention(s) 3 Positive mention(s) 6 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Arrowhead Pharmaceuticals 0 Very Positive mention(s) 3 Positive mention(s) 3 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Neutral

Arrowhead Pharmaceuticals (ARWR) Competitors

$62.31 +1.57 (+2.58%)

As of 12:14 PM Eastern

Compare

ARWR vs. BIIB, ALNY, ROIV, BNTX, and INSM

Should you buy Arrowhead Pharmaceuticals stock or one of its competitors? Arrowhead Pharmaceuticals's main competitors and comparable companies include Biogen (BIIB), Alnylam Pharmaceuticals (ALNY), Roivant Sciences (ROIV), BioNTech (BNTX), and Insmed (INSM). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Arrowhead Pharmaceuticals compare to Biogen?

Arrowhead Pharmaceuticals (NASDAQ:ARWR) and Biogen (NASDAQ:BIIB) are both healthcare companies, but which is the superior stock? We will contrast the two companies based on the strength of their profitability, dividends, institutional ownership, risk, earnings, valuation, media sentiment and analyst recommendations.

Arrowhead Pharmaceuticals currently has a consensus price target of $98.31, suggesting a potential upside of 61.85%. Biogen has a consensus price target of $230.00, suggesting a potential upside of 5.30%. Given Arrowhead Pharmaceuticals' stronger consensus rating and higher probable upside, analysts plainly believe Arrowhead Pharmaceuticals is more favorable than Biogen.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Arrowhead Pharmaceuticals	1 Sell rating(s)	3 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.64
Biogen	1 Sell rating(s)	13 Hold rating(s)	17 Buy rating(s)	1 Strong Buy rating(s)	2.56

Biogen has a net margin of 8.32% compared to Arrowhead Pharmaceuticals' net margin of -47.79%. Biogen's return on equity of 11.18% beat Arrowhead Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Arrowhead Pharmaceuticals	-47.79%	-60.06%	-17.37%
Biogen	8.32%	11.18%	6.88%

Biogen has higher revenue and earnings than Arrowhead Pharmaceuticals. Arrowhead Pharmaceuticals is trading at a lower price-to-earnings ratio than Biogen, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Arrowhead Pharmaceuticals	$829.45M	10.32	-$1.63M	-$2.25	N/A
Biogen	$9.89B	3.26	$1.29B	$5.65	38.66

Arrowhead Pharmaceuticals has a beta of 1.29, indicating that its stock price is 29% more volatile than the broader market. Comparatively, Biogen has a beta of 0.09, indicating that its stock price is 91% less volatile than the broader market.

In the previous week, Biogen had 11 more articles in the media than Arrowhead Pharmaceuticals. MarketBeat recorded 19 mentions for Biogen and 8 mentions for Arrowhead Pharmaceuticals. Biogen's average media sentiment score of 0.74 beat Arrowhead Pharmaceuticals' score of 0.26 indicating that Biogen is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Arrowhead Pharmaceuticals	0 Very Positive mention(s)	3 Positive mention(s)	3 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Neutral
Biogen	7 Very Positive mention(s)	4 Positive mention(s)	5 Neutral mention(s)	1 Negative mention(s)	1 Very Negative mention(s)	Positive

62.6% of Arrowhead Pharmaceuticals shares are held by institutional investors. Comparatively, 87.9% of Biogen shares are held by institutional investors. 3.6% of Arrowhead Pharmaceuticals shares are held by insiders. Comparatively, 0.3% of Biogen shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Summary

Biogen beats Arrowhead Pharmaceuticals on 12 of the 17 factors compared between the two stocks.

How does Arrowhead Pharmaceuticals compare to Alnylam Pharmaceuticals?

Alnylam Pharmaceuticals (NASDAQ:ALNY) and Arrowhead Pharmaceuticals (NASDAQ:ARWR) are both healthcare companies, but which is the better stock? We will contrast the two companies based on the strength of their dividends, profitability, earnings, media sentiment, valuation, analyst recommendations, risk and institutional ownership.

93.0% of Alnylam Pharmaceuticals shares are held by institutional investors. Comparatively, 62.6% of Arrowhead Pharmaceuticals shares are held by institutional investors. 0.9% of Alnylam Pharmaceuticals shares are held by insiders. Comparatively, 3.6% of Arrowhead Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Alnylam Pharmaceuticals has a beta of 0.28, meaning that its stock price is 72% less volatile than the broader market. Comparatively, Arrowhead Pharmaceuticals has a beta of 1.29, meaning that its stock price is 29% more volatile than the broader market.

Alnylam Pharmaceuticals has higher revenue and earnings than Arrowhead Pharmaceuticals. Arrowhead Pharmaceuticals is trading at a lower price-to-earnings ratio than Alnylam Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Alnylam Pharmaceuticals	$3.71B	8.09	$313.75M	$5.38	41.73
Arrowhead Pharmaceuticals	$829.45M	10.32	-$1.63M	-$2.25	N/A

Alnylam Pharmaceuticals presently has a consensus target price of $366.65, suggesting a potential upside of 63.30%. Arrowhead Pharmaceuticals has a consensus target price of $98.31, suggesting a potential upside of 61.85%. Given Alnylam Pharmaceuticals' stronger consensus rating and higher possible upside, equities research analysts clearly believe Alnylam Pharmaceuticals is more favorable than Arrowhead Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Alnylam Pharmaceuticals	0 Sell rating(s)	6 Hold rating(s)	16 Buy rating(s)	3 Strong Buy rating(s)	2.88
Arrowhead Pharmaceuticals	1 Sell rating(s)	3 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.64

Alnylam Pharmaceuticals has a net margin of 15.26% compared to Arrowhead Pharmaceuticals' net margin of -47.79%. Alnylam Pharmaceuticals' return on equity of 84.93% beat Arrowhead Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Alnylam Pharmaceuticals	15.26%	84.93%	14.30%
Arrowhead Pharmaceuticals	-47.79%	-60.06%	-17.37%

In the previous week, Alnylam Pharmaceuticals had 8 more articles in the media than Arrowhead Pharmaceuticals. MarketBeat recorded 16 mentions for Alnylam Pharmaceuticals and 8 mentions for Arrowhead Pharmaceuticals. Alnylam Pharmaceuticals' average media sentiment score of 0.51 beat Arrowhead Pharmaceuticals' score of 0.26 indicating that Alnylam Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Alnylam Pharmaceuticals	4 Very Positive mention(s)	2 Positive mention(s)	5 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Positive
Arrowhead Pharmaceuticals	0 Very Positive mention(s)	3 Positive mention(s)	3 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

Alnylam Pharmaceuticals beats Arrowhead Pharmaceuticals on 14 of the 17 factors compared between the two stocks.

How does Arrowhead Pharmaceuticals compare to Roivant Sciences?

Arrowhead Pharmaceuticals (NASDAQ:ARWR) and Roivant Sciences (NASDAQ:ROIV) are both healthcare companies, but which is the better stock? We will contrast the two companies based on the strength of their dividends, risk, earnings, analyst recommendations, valuation, media sentiment, institutional ownership and profitability.

62.6% of Arrowhead Pharmaceuticals shares are held by institutional investors. Comparatively, 64.8% of Roivant Sciences shares are held by institutional investors. 3.6% of Arrowhead Pharmaceuticals shares are held by insiders. Comparatively, 8.8% of Roivant Sciences shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Arrowhead Pharmaceuticals presently has a consensus price target of $98.31, suggesting a potential upside of 61.85%. Roivant Sciences has a consensus price target of $45.64, suggesting a potential upside of 33.40%. Given Arrowhead Pharmaceuticals' higher probable upside, equities research analysts clearly believe Arrowhead Pharmaceuticals is more favorable than Roivant Sciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Arrowhead Pharmaceuticals	1 Sell rating(s)	3 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.64
Roivant Sciences	1 Sell rating(s)	1 Hold rating(s)	10 Buy rating(s)	1 Strong Buy rating(s)	2.85

Arrowhead Pharmaceuticals has higher revenue and earnings than Roivant Sciences. Roivant Sciences is trading at a lower price-to-earnings ratio than Arrowhead Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Arrowhead Pharmaceuticals	$829.45M	10.32	-$1.63M	-$2.25	N/A
Roivant Sciences	$8.26M	2,991.59	-$299.77M	-$0.53	N/A

Arrowhead Pharmaceuticals has a net margin of -47.79% compared to Roivant Sciences' net margin of -3,534.96%. Roivant Sciences' return on equity of -22.94% beat Arrowhead Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Arrowhead Pharmaceuticals	-47.79%	-60.06%	-17.37%
Roivant Sciences	-3,534.96%	-22.94%	-21.53%

In the previous week, Roivant Sciences had 4 more articles in the media than Arrowhead Pharmaceuticals. MarketBeat recorded 12 mentions for Roivant Sciences and 8 mentions for Arrowhead Pharmaceuticals. Roivant Sciences' average media sentiment score of 0.64 beat Arrowhead Pharmaceuticals' score of 0.26 indicating that Roivant Sciences is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Arrowhead Pharmaceuticals	0 Very Positive mention(s)	3 Positive mention(s)	3 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Neutral
Roivant Sciences	6 Very Positive mention(s)	2 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Arrowhead Pharmaceuticals has a beta of 1.29, indicating that its share price is 29% more volatile than the broader market. Comparatively, Roivant Sciences has a beta of 1.1, indicating that its share price is 10% more volatile than the broader market.

Summary

Roivant Sciences beats Arrowhead Pharmaceuticals on 9 of the 16 factors compared between the two stocks.

How does Arrowhead Pharmaceuticals compare to BioNTech?

BioNTech (NASDAQ:BNTX) and Arrowhead Pharmaceuticals (NASDAQ:ARWR) are both healthcare companies, but which is the better stock? We will contrast the two businesses based on the strength of their dividends, institutional ownership, media sentiment, earnings, analyst recommendations, risk, profitability and valuation.

15.5% of BioNTech shares are owned by institutional investors. Comparatively, 62.6% of Arrowhead Pharmaceuticals shares are owned by institutional investors. 19.2% of BioNTech shares are owned by insiders. Comparatively, 3.6% of Arrowhead Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

BioNTech currently has a consensus target price of $125.69, indicating a potential upside of 36.53%. Arrowhead Pharmaceuticals has a consensus target price of $98.31, indicating a potential upside of 61.85%. Given Arrowhead Pharmaceuticals' higher possible upside, analysts plainly believe Arrowhead Pharmaceuticals is more favorable than BioNTech.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
BioNTech	1 Sell rating(s)	6 Hold rating(s)	12 Buy rating(s)	1 Strong Buy rating(s)	2.65
Arrowhead Pharmaceuticals	1 Sell rating(s)	3 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.64

Arrowhead Pharmaceuticals has lower revenue, but higher earnings than BioNTech. Arrowhead Pharmaceuticals is trading at a lower price-to-earnings ratio than BioNTech, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
BioNTech	$3.25B	7.17	-$1.29B	-$7.83	N/A
Arrowhead Pharmaceuticals	$829.45M	10.32	-$1.63M	-$2.25	N/A

BioNTech has a beta of 1.25, meaning that its share price is 25% more volatile than the broader market. Comparatively, Arrowhead Pharmaceuticals has a beta of 1.29, meaning that its share price is 29% more volatile than the broader market.

Arrowhead Pharmaceuticals has a net margin of -47.79% compared to BioNTech's net margin of -63.54%. BioNTech's return on equity of -6.86% beat Arrowhead Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
BioNTech	-63.54%	-6.86%	-6.00%
Arrowhead Pharmaceuticals	-47.79%	-60.06%	-17.37%

In the previous week, BioNTech had 14 more articles in the media than Arrowhead Pharmaceuticals. MarketBeat recorded 22 mentions for BioNTech and 8 mentions for Arrowhead Pharmaceuticals. BioNTech's average media sentiment score of 0.46 beat Arrowhead Pharmaceuticals' score of 0.26 indicating that BioNTech is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
BioNTech	9 Very Positive mention(s)	3 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Arrowhead Pharmaceuticals	0 Very Positive mention(s)	3 Positive mention(s)	3 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

BioNTech beats Arrowhead Pharmaceuticals on 10 of the 17 factors compared between the two stocks.

How does Arrowhead Pharmaceuticals compare to Insmed?

Insmed (NASDAQ:INSM) and Arrowhead Pharmaceuticals (NASDAQ:ARWR) are both healthcare companies, but which is the better investment? We will compare the two companies based on the strength of their risk, dividends, analyst recommendations, institutional ownership, media sentiment, valuation, earnings and profitability.

Arrowhead Pharmaceuticals has higher revenue and earnings than Insmed. Arrowhead Pharmaceuticals is trading at a lower price-to-earnings ratio than Insmed, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Insmed	$606.42M	36.18	-$1.28B	-$4.11	N/A
Arrowhead Pharmaceuticals	$829.45M	10.32	-$1.63M	-$2.25	N/A

Arrowhead Pharmaceuticals has a net margin of -47.79% compared to Insmed's net margin of -76.94%. Arrowhead Pharmaceuticals' return on equity of -60.06% beat Insmed's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Insmed	-76.94%	-123.94%	-44.30%
Arrowhead Pharmaceuticals	-47.79%	-60.06%	-17.37%

In the previous week, Insmed had 4 more articles in the media than Arrowhead Pharmaceuticals. MarketBeat recorded 12 mentions for Insmed and 8 mentions for Arrowhead Pharmaceuticals. Arrowhead Pharmaceuticals' average media sentiment score of 0.26 beat Insmed's score of 0.05 indicating that Arrowhead Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Insmed	1 Very Positive mention(s)	3 Positive mention(s)	6 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
Arrowhead Pharmaceuticals	0 Very Positive mention(s)	3 Positive mention(s)	3 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Neutral

Insmed has a beta of 0.83, indicating that its stock price is 17% less volatile than the broader market. Comparatively, Arrowhead Pharmaceuticals has a beta of 1.29, indicating that its stock price is 29% more volatile than the broader market.

Insmed currently has a consensus price target of $200.57, indicating a potential upside of 99.61%. Arrowhead Pharmaceuticals has a consensus price target of $98.31, indicating a potential upside of 61.85%. Given Insmed's stronger consensus rating and higher possible upside, equities research analysts plainly believe Insmed is more favorable than Arrowhead Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Insmed	1 Sell rating(s)	0 Hold rating(s)	23 Buy rating(s)	1 Strong Buy rating(s)	2.96
Arrowhead Pharmaceuticals	1 Sell rating(s)	3 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.64

62.6% of Arrowhead Pharmaceuticals shares are held by institutional investors. 2.1% of Insmed shares are held by company insiders. Comparatively, 3.6% of Arrowhead Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Summary

Arrowhead Pharmaceuticals beats Insmed on 10 of the 17 factors compared between the two stocks.

Get Arrowhead Pharmaceuticals News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ARWR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

ARWR vs. The Competition

Export

Metric	Arrowhead Pharmaceuticals	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$8.77B	$3.88B	$7.20B	$13.28B
Dividend Yield	N/A	3.65%	2.53%	16.36%
P/E Ratio	-27.67	13.29	274.63	26.11
Price / Sales	10.58	1,195.64	586.31	81.01
Price / Cash	514.91	117.60	76.82	53.72
Price / Book	17.12	16.46	10.93	6.31
Net Income	-$1.63M	-$22.69M	$3.50B	$381.90M
7 Day Performance	-2.93%	-1.44%	-0.94%	-1.34%
1 Month Performance	-24.59%	-9.73%	-5.45%	-4.31%
1 Year Performance	72.79%	10.19%	4.43%	-0.35%

Arrowhead Pharmaceuticals Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
ARWR Arrowhead Pharmaceuticals	2.728 of 5 stars	$62.31 +2.6%	$98.31 +57.8%	+64.4%	$8.77B	$829.45M	N/A	711
BIIB Biogen	3.3635 of 5 stars	$223.59 +1.7%	$230.14 +2.9%	+44.7%	$32.49B	$9.89B	39.57	7,500	Analyst Forecast
ALNY Alnylam Pharmaceuticals	4.2373 of 5 stars	$219.89 +0.1%	$366.90 +66.9%	-50.2%	$29.40B	$3.71B	40.87	2,770	Analyst Forecast Insider Trade
ROIV Roivant Sciences	3.2524 of 5 stars	$35.78 +0.2%	$45.64 +27.5%	+113.4%	$25.80B	$8.26M	N/A	721
BNTX BioNTech	4.0984 of 5 stars	$97.64 +0.8%	$126.00 +29.0%	-13.4%	$24.50B	$3.25B	N/A	7,807	Analyst Forecast Insider Trade

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:ARWR) was last updated on 10/9/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Arrowhead Pharmaceuticals (ARWR) Competitors

ARWR vs. BIIB, ALNY, ROIV, BNTX, and INSM

How does Arrowhead Pharmaceuticals compare to Biogen?

Summary

How does Arrowhead Pharmaceuticals compare to Alnylam Pharmaceuticals?

Summary

How does Arrowhead Pharmaceuticals compare to Roivant Sciences?

Summary

How does Arrowhead Pharmaceuticals compare to BioNTech?

Summary

How does Arrowhead Pharmaceuticals compare to Insmed?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ARWR vs. The Competition

Arrowhead Pharmaceuticals Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Arrowhead Pharmaceuticals (ARWR) Competitors

ARWR vs. BIIB, ALNY, ROIV, BNTX, and INSM

How does Arrowhead Pharmaceuticals compare to Biogen?

Do analysts recommend ARWR or BIIB?

Is ARWR or BIIB more profitable?

Which has higher earnings & valuation, ARWR or BIIB?

Which has more risk and volatility, ARWR or BIIB?

Does the media favor ARWR or BIIB?

Do institutionals & insiders hold more shares of ARWR or BIIB?

Summary

How does Arrowhead Pharmaceuticals compare to Alnylam Pharmaceuticals?

Do institutionals and insiders have more ownership in ALNY or ARWR?

Which has more risk and volatility, ALNY or ARWR?

Which has stronger earnings and valuation, ALNY or ARWR?

Do analysts prefer ALNY or ARWR?

Is ALNY or ARWR more profitable?

Does the media refer more to ALNY or ARWR?

Summary

How does Arrowhead Pharmaceuticals compare to Roivant Sciences?

Do institutionals and insiders have more ownership in ARWR or ROIV?

Do analysts rate ARWR or ROIV?

Which has higher earnings & valuation, ARWR or ROIV?

Is ARWR or ROIV more profitable?

Does the media prefer ARWR or ROIV?

Which has more volatility & risk, ARWR or ROIV?

Summary

How does Arrowhead Pharmaceuticals compare to BioNTech?

Do insiders & institutionals have more ownership in BNTX or ARWR?

Do analysts recommend BNTX or ARWR?

Which has preferable valuation & earnings, BNTX or ARWR?

Which has more risk & volatility, BNTX or ARWR?

Is BNTX or ARWR more profitable?

Does the media refer more to BNTX or ARWR?

Summary

How does Arrowhead Pharmaceuticals compare to Insmed?

Which has preferable earnings & valuation, INSM or ARWR?

Is INSM or ARWR more profitable?

Does the media refer more to INSM or ARWR?

Which has more volatility and risk, INSM or ARWR?

Do analysts prefer INSM or ARWR?

Do insiders and institutionals have more ownership in INSM or ARWR?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ARWR vs. The Competition

Arrowhead Pharmaceuticals Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools